The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Measles is a disease caused by the virus Morbillivirus hominis. It’s an RNA virus in the family Paramyxoviridae—meaning it’s ...

Influenza viruses like bird flu can mix and match their genomes, and this has played a role in at least three of the last ...

NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...

Testing at India’s National Institute of Virology has confirmed a third recent Nipah virus case from India’s Kerla state, ...

The disease was found following tests on a severely emaciated doe that was euthanized and tested in early June, Andrea Korman ...

Respiratory Syncytial Virus (RSV) is a major cause of acute respiratory tract infections (ARTIs) and can trigger outbreaks in vulnerable settings such as nursing homes, pediatric wards, and neonatal ...

Background Respiratory syncytial virus (RSV) remains the leading cause of serious viral bronchiolitis and pneumonia in infants and young children throughout the world. The burden of disease is ...

Background: Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory infections in children, yet biomarkers for assessing disease severity remain limited. Herein, we ...

About RSV Respiratory syncytial virus (RSV) is a contagious virus that causes widespread seasonal infections and can lead to serious respiratory conditions such as bronchiolitis and pneumonia.

About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower ...